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Introduction: Glioblastoma multiforme (GBM) is the most frequent and aggressive 
malignant brain tumour, with a poor prognosis despite available surgical and radio-
chemotherapy, rising the necessity for searching alternative therapies. Several preclinical 
studies evaluating the efficacy of cannabinoids in animal models of GBM have been 
described, but the diversity of experimental conditions and of outcomes hindered 
definitive conclusions about cannabinoids efficacy.  
Methods: A search in different databases (Pubmed, Web of Science, Scopus and SciELO) 
was conducted during June 2019 to systematically identify publications evaluating the 
effects of cannabinoids in murine xenografts models of GBM. The tumour volume and 
number of animals were extracted, and a random effects meta-analysis of these results 
was performed to estimate the efficacy of cannabinoids. The impact of different 
experimental factors and publication bias on the efficacy of cannabinoids was also 
assessed. 
Results: Nine publications, which satisfied the inclusion criteria, were identified and 
subdivided in 22 studies involving 301 animals. Overall, cannabinoid therapy reduced the 
fold of increase in tumour volume in animal models of GBM, when compared with 
untreated controls. The overall weighted standardized difference in means (WSDM) for 
the effect of cannabinoids was -1.399 (95% CI: -1.900 to -0.898; p-value<0.0001). 
Furthermore, treatment efficacy was observed for different types of cannabinoids, alone 
or in combination, and for different treatment durations. Cannabinoid therapy was still 
effective after correcting for publication bias. 
Conclusions: The results indicate that cannabinoids reduce the tumour growth in animal 













The incidence in adults of newly diagnosed glioblastomas is 0.59-3.69 cases per 100,000- 
person life-years (Dumitru et al., 2018). Glioblastoma multiforme (GBM), also known as 
grade IV astrocytoma, is simultaneously the most common class of malignant brain 
tumours and one of the most aggressive types of cancer. Therefore, after the diagnostic, 
patients usually live just more 6-12 months, which is related mostly with the high 
invasiveness and proliferation rate of GBM (Velasco et al., 2007). The existing guidelines 
for therapeutic approaches to treat GBM (surgical resection and focal radiotherapy) are 
simply palliative (Guzmán et al., 2006). Several chemotherapeutic compounds, such as 
alkylating agents (e.g. temozolomide – TMZ) and nitrosoureas (e.g. carmustine) have also 
been assessed, but increase in survival of patients was only moderate (Guzmán et al., 
2006). Only TMZ showed some clinical efficacy in a phase III clinical trial (Stupp et al., 
2005). Furthermore, GBM presents a high-level of resistance to the standard 
chemotherapy and radiotherapy (Torres et al., 2011). For that reason, the search for new 
promising compounds to treat GBM is essential. 
Cannabinoids, the bioactive compounds of Cannabis sativa L., exert their effects using 
certain types of G-proteins coupled receptors, which are usually triggered by a group of 
endogenous ligands, the endocannabinoids (Blázquez et al., 2008). The endocannabinoid 
system was found when studying the main bioactive compound of C. sativa, Δ9-
tetrahydrocannabinol (THC) (Allister et al., 2005). 
Several preclinical experiments indicate that drugs mimicking the endocannabinoid 
system may be applied to prevent cancer growth (Rocha et al., 2014). In fact, it was 
demonstrated that cannabinoids may be able to regulate both the cell growth and death in 
various types of cancer (Allister et al., 2005). In early 2000 were published the first 
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studies demonstrating the anti-tumour effects of several cannabinoids in animal models 
of glioma (Massi et al., 2004; Recht et al., 2001; Sánchez et al., 2001a). These studies 
encouraged the first pilot phase I clinical trial including a reduced number of patients 
(Guzmán et al., 2006), which showed safety of THC administration and indicated its anti-
proliferative activity. Since then, several preclinical studies using animal models were 
published, most of them reporting the capacity of cannabinoids in reducing the 
progression of GBM (Dumitru et al., 2018; Erices et al., 2018; McAllister et al., 2015; 
Rocha et al., 2014). 
The use of animal models is of major importance in research aiming the improvement of 
human health care (Hooijmans et al., 2014). Although some recent reviews had been 
published reporting animal studies of anti-tumour effect of cannabinoids on GBM 
(Dumitru et al., 2018; Erices et al., 2018), a meta-analysis of these studies was not 
performed yet. There are several benefits in conducting meta-analyses on data from 
animal studies; they can be used to inform clinical trial design, or to test and explain 
discrepancies between preclinical and clinical trial results (Vesterinen et al., 2014). 
The objective of this work was to perform a systematic review, complying with the 
PRISMA (Preferred Reported Items for Systematic Reviews and Meta-Analysis) 
statement, followed by meta-analysis of results obtained using animal models on the 




2.1. Search strategy, inclusion criteria and study selection 
The electronic search for this systematic review was undertaken on various databases 
(Pubmed, Web of Science, Scopus and SciELO) during June 2019. The databases were 
queried using the Boolean operator tools, with the following strategy: (cannabinoid* OR 
cannabi*) AND (glioblastoma OR astrocytoma OR glioma OR oligodendroglioma OR 
GBM OR glioblastoma multiforme). The references of the articles considered relevant 
were also verified to find additional works. Following the PRISMA statement (Moher et 
al., 2015, 2009), titles and abstracts of the selected articles were firstly screened and the 
full texts of those considered important were then analysed in detail. The literature 
selection procedure was performed independently by two authors, being a third consulted 
in case of disagreements. To be included in this systematic review, studies must 
accomplish the following criteria: to use human-derived cells in animal models 
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(xenografts), to present a control group (vehicle), to show the result of the outcome 
(tumour volume) at the beginning and at the end of the treatment with cannabinoids, and 
to indicate the standard deviation (SD) of the measurements and the animal number per 
group. 
 
2.2. Risk of bias assessment 
The methodological quality of the includes studies was evaluated by a 9-item quality 
checklist adapted from the CAMARADES (Collaborative Approach to Meta-Analysis 
and Review of Animal Data in Experimental Studies) published criteria, which comprise: 
1) publication in a peer-reviewed journal; 2) reporting the number of tumour cells 
implanted; 3) reporting the randomized allocation of tumour-bearing animals to treatment 
and control groups; 4) blinded assessment of outcome; 5) sample size calculation; 6) 
compliance with animal welfare regulations; 7) potential conflicts of interest; 8) number 
of animals originally inoculated with tumour cells; and 9) explanation of any treated 
animals excluded from analysis (J. A. Hirst et al., 2014; T. C. Hirst et al., 2014). 
 
2.3. Data extraction and synthesis 
After the selection of the studies, the included ones were carefully analysed and the 
following data were extracted and summarized: first author’s last name, year of 
publication, type of GBM cells and intervention, tumour implantation site, outcome 
analysed, model used, dose of cannabinoid(s) and duration of the treatment. The revision 
and extraction of the data were independently performed by two authors applying a 
prespecified protocol, being a third reviewer consulted to analyse discrepancies in data 
extraction. The results extracted were both initial and post-intervention mean values of 
tumour volume with the corresponding SD and were then converted in terms of fold of 
increase. The results of tumour volume were generally reported in Figures in the original 
studies, and for that reason the Inkscape program (Version 0.92.4) was used to obtain the 
numerical values to perform the statistical analysis. 
 
2.4. Statistical analyses 
The present meta-analysis was performed to clarify the effects of cannabinoids on GBM 
growth by summarizing the results of studies in which the cannabinoids were 
administered in animals inoculated with human-derived GBM cells. For the outcome of 
interest, an assessment was performed on the pooled effect of the treatment with 
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cannabinoids in terms of weighted standardized difference in means (WSDM) between 
the change from pre- and post-treatment mean values of the intervention and control 
groups. Data statistical analysis was undertaken using Comprehensive Meta-Analysis 
software (Version 2.0) by introducing the number of animals, the fold of increase and 
respective SD values of the outcome for intervention and control groups, being the 
random effects model employed (Borenstein et al., 2009). Forest plots were generated to 
illustrate the study-specific effect sizes along with a 95% confidence interval (CI). The 
statistic I2 of Higgins was used as a measure of inconsistency across the findings of the 
included studies. The scale of I2 has a range of 0 to 100% and values on the order of 25%, 
50% and 75% are considered low, moderate and high heterogeneity, respectively 
(Higgins et al., 2003). Subgroup analysis was performed on the outcome under study, per 
the model used, type of cannabinoids and duration of the treatment, in order to evaluate 
the impact of these experimental factors on the cannabinoid effect size and to explore 
potential sources of heterogeneity. The Chi-square test was employed to assess whether 
there is homogeneity between the different subgroups with respect to the effect under 
study. 
Three different analyses were used to assess the potential impact of publication bias on 
the present meta-analysis: 1) Funnel plot (Light et al., 1994; Light and Pillemer, 1984); 
2) Egger’s regression test (Borenstein et al., 2009; Egger et al., 1997); 3) Duval and 
Tweedie’s Trim and Fill approach (Duval and Tweedie, 2000a, 2000b), which allows the 
best estimate of the unbiased pooled effect size to be obtained and creates a funnel plot 
that includes both the observed studies (shown as blue circles) and the necessary imputed 
studies (shown as red circles) to obtain the absence of bias. 
The sensitivity analysis was also achieved by eliminating each study one at a time to 
evaluate the stability of the results.  
 
3. Results 
3.1. Search and selection of studies 
Among the 40 articles initially identified, 9 met all the inclusion criteria for this 
systematic review. Figure 1 shows the detailed steps of the article selection process. From 
the 16 full-text articles assessed for eligibility, 7 were excluded. The reasons for exclusion 
were mostly the inconsistency in presenting the results (tumour perimeter, weight, 
diameter) (Duntsch et al., 2006; Recht et al., 2001; Silva et al., 2019), different study 
designs (Aguado et al., 2007; Singer et al., 2015; Soroceanu et al., 2013) and different 
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summary statistics (median) (Fisher et al., 2016). Six of the 9 included studies were 
divided into different experiments. Finally, 22 studies, totalizing 301 animals, were 
included in this systematic review and meta-analysis. 
 
3.2. Included studies and characteristics 
The principal characteristics of the included studies are outlined in Table 1. The studies 
cover a broad spectrum of cannabinoids both natural and synthetic, together with several 
types of human-derived GBM cells, which were applied in different types of animal 
models (xenografts). Furthermore, the cannabinoids were administered to the animals 
alone or in combination with each other at different doses. Such variables were included 
in this meta-analysis to explore potential sources of heterogeneity.  
 
3.3. Risk of bias 
The Supplementary Table 1 shows the study quality scores assessed using the 
CAMARADES checklist. All the included studies are peer-reviewed publications, 
reported the number of tumour cells implanted and referred the randomization of the 
animals for both treatment and control groups. However, none of the studies reported the 
blind of outcome assessment and have calculated the sample size. Overall, the global 
quality of the included studies is good (quality scores superior to 4 in a total of 9). 
 
3.4. Effects of cannabinoids on GBM growth 
The meta-analysis results of the effects of cannabinoids on GBM growth are graphically 
reported on Figure 2, being the overall results presented in Table 2. It is possible to verify 
that cannabinoids were able to significantly reduce (p-value<0.0001) the mean fold of 
increase of tumour volume (WSDM: -1.399; 95% CI: -1.900 to -0.898), indicating that, 
in fact, these compounds acted against GBM. It should be noted that, nevertheless, 
moderate heterogeneity was observed (I2=72%). 
 
3.5. Subgroup and sensitivity analyses 
A subgroup analysis was also undertaken (Table 3) to evaluate the influence of the model 
used, type of cannabinoids and treatment duration. Regarding the model used, only for 
subcutaneous xenografts was obtained a significant reduction (p-value<0.0001) of the 
mean fold of increase of tumour volume (WSDM: -1.512; 95% CI: -2.060 to -0.965). 
However, for intracranial xenografts only 2 studies were considered, which may explain 
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the absence of statistical significance in this subgroup. Nevertheless, the model used did 
not account for a significant proportion of the observed heterogeneity (Chi2=1.082; p-
value=0.298). Concerning the type of cannabinoids, all of them were able to significantly 
reduce the fold of increase of tumour volume, except the cannabinoid KM-233, but in this 
case the number of studies, two, is too low to draw definitive conclusions. Regarding the 
heterogeneity between the types of cannabinoid, it was low for cannabidiol (CBD) but 
high for THC studies. In fact, the type of cannabinoid explained a significant proportion 
of the observed heterogeneity, according to the Chi-square test (Chi2=14.219; p-
value=0.007). Concerning the treatment duration, it did not account for a significant 
proportion of heterogeneity (Chi2=1.535; p-value=0.675), but it is difficult to establish a 
definitive conclusion because only one study was considered for both treatments with 8 
and 35 weeks. For treatments with 12-15 weeks and 22-27 weeks, significant reduction 
of the fold of increase of the tumour volume was observed.  
The sensitivity analysis was also performed by excluding one or more studies from the 
analysis to see how this affected the results. The results showed that the pooled effects of 
cannabinoids on GBM growth did not change substantially if a single or a few studies 
were omitted (Figure 3). Overall, the sensitivity analysis demonstrated that the findings 
of this meta-analysis are robust. 
 
3.6. Publication bias 
To analyse the publication bias, a funnel plot was generated for the outcome considering 
the Trim and Fill adjustment (Figure 4). It was observed that there are more studies on 
the right than on the left, and for that reason 2 studies were inputted on the left to adjust 
the funnel plot to the absence of publication bias. The WSDM both observed and adjusted 
were reported on Tables 2 and 3. 
The presence of publication bias was explored using Egger's regression test. This test 
indicates evidence of publication bias for the impact of cannabinoids administration on 
GBM growth. (Table 4). 
 
4. Discussion 
In this systematic review with meta-analysis of 9 publications, subdivided in 22 studies 
and involving 301 animals, we found that overall cannabinoid therapy reduced tumour 
volume in murine xenografts models of GBM. Furthermore, treatment efficacy was 
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observed for different types of cannabinoids, alone or in combination, and different 
treatment durations.  
Several previous in vitro and in vivo pre-clinical studies in animal models and pilot studies 
in human patients (Allister et al., 2005; Guzmán et al., 2006; Ladin et al., 2016) had 
reported the therapeutic potential of cannabinoids on GBM, based on reduction of tumour 
growth. However, to the best of our knowledge, the present work is the first systematic 
review with meta-analysis performed regarding the effects of cannabinoids on GBM. 
In the present meta-analysis, the outcome analysed was the fold of increase from initial 
tumour volume before treatment, rather than median survival time, since most of the 
studies reported the initial and final volume, or the fold of increase in tumour volume, 
together with the respective SD or standard error of mean (SEM). 
Regarding the site of tumour inoculation, most of the studies included in the present meta-
analysis used heterotopic subcutaneous xenografts, with only 2 studies using orthotopic 
intracranial xenografts. Only for the subcutaneous xenograft model, a significant 
reduction of tumour volume by cannabinoids was found. Nevertheless, there was no 
significant variation in cannabinoids effect between tumour models. 
The subgroup analysis for different cannabinoids, revealed that most cannabinoids, either 
natural or synthetic and either alone or in combination, were able to reduce tumour 
volume of murine GBM models, except for the synthetic cannabinoid KM-233. However, 
the effect of the different cannabinoids varied, and the type of cannabinoid showed to be 
a significant source of heterogeneity. Concerning the duration of treatment with 
cannabinoids, a significant decrease of tumour volume was obtained for the 12-15 weeks 
and for the 22-27 weeks treatment periods. There was no significant variation between 
different treatment duration. 
In the present analysis, only the studies reporting animals inoculated with tumour cells of 
human origin were considered. This choice aimed to reduce the heterogeneity among the 
studies. On the other hand, using cells of human origin constitute a more reliable 
model/construct of GBM and previous studies suggest that human-derived tumours are 
more sensitive to chemotherapy than those originated in rodents (Amarasingh et al., 
2009).  
The overall global quality of the studies included in the present meta-analysis was good. 
The publication bias of the present meta-analysis was also assessed, and the results 
indicate its presence, which is usually due to the fact of neutral studies often remain 
unpublished or take longer to get published than those reporting statistically significant 
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results, as previously mentioned (Sena et al., 2014). However, probably this was not the 
case for the studies considered in the present meta-analysis, since, after correcting for 
publication bias, the adjusted WSDM was more negative, suggesting a stronger reduction 
on tumour volume induced by cannabinoids, than the non-adjusted value. However, we 
cannot exclude that other confounding effects of certain aspects of studies design 
(including randomization, allocation concealment and blinded outcome assessment) 
might also constitute source of bias, as commonly happens with animal studies 
(Amarasingh et al., 2009). 
In the present meta-analysis, the results in general presented moderate or high 
heterogeneity, even after subgrouping for site of cell tumour inoculation, type of 
cannabinoid or treatment duration. This is common in meta-analysis dealing with data 
obtained from animal models (Hooijmans et al., 2014), where the cause of heterogeneity 
is difficult to identify due to experimental differences between studies. Nevertheless, 
animal studies are crucial to the understanding of disease mechanisms and for testing 
interventions for safety and efficacy.  
The promising results obtained in animal models of GBM, led to 3 pilot clinical trials to 
assess the efficacy of cannabinoids in GBM patients (Dall’Stella et al., 2019; Guzmán et 
al., 2006; Kenyon et al., 2018). The first study, conducted performed in 2006 and 
enrolling including 9 patients, showed safety ofthat THC was safe; however, no clear 
activity of THC on tumour progression was reported (Guzmán et al., 2006). The study of 
Kenyon, et al 2018 (Kenyon et al., 2018), enrolled 7 patients treated with CBD and 
reported extended survival in 4 and slowed disease progression in 3 of the patients. The 
study of Dall'Stella, et al 2019 (Dall’Stella et al., 2019) enrolled only 2 patients submitted 
to chemoradiation followed by a multiple drug regimen (procarbazine, lomustine, and 
vincristine) plus CBD, both patients showed no signs of disease progression for at least 2 
years.  
The chemotherapeutic options to treat GBM are, in fact, limited. Only TMZ showed 
clinical efficacy, although modest, in a phase III clinical trial (Stupp et al., 2005), the 
median survival increasing from 12.1 months with radiotherapy alone to 14.6 months 
with radiotherapy plus TMZ. Therefore, the potential use of cannabinoids, alone or in 
combination with other drugs or radiotherapy, to treat GBM deserves further 
investigation.  
Preclinical studies using animal models of GBM, showed that cannabinoids in 
combination with TMZ produced a stronger anti-tumoural effect than the effect of each 
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drug alone (Blázquez et al., 2008; López-Valero et al., 2018a, 2018b). In fact, a phase II 
clinical trial of 21 patients had been recently conducted. This trial showed that patients 
treated with a combination of THC and CBD in addition to TMZ had a median survival 
of >662 days compared with 369 days in the group treated with TMZ alone (Schultz and 
Beyer, 2017).  
In vitro studies showed that cannabinoids may reduce tumour growth by: 1) inducing 
apoptosis and cytotoxic autophagy); 2) inhibiting cell proliferation, and 3) inhibiting-
angiogenesis (Dumitru et al., 2018). Cannabinoid-induced activation of the intrinsic 
apoptotic pathway and of autophagy in GBM cells, seems to be mediated by increased 
ceramide production (Dumitru et al., 2018). Another mechanism by which cannabinoids 
induce GBM cell apoptosis involves increased ROS production and oxidative stress 
(Massi et al., 2010). Increased ROS-production also showed to mediate cannabinoids-
induced inhibition of glioma stem cells self-renewal (Singer et al., 2015). On the other 
hand, THC inhibits the cell cycle progression in GBM by decreasing the levels of E2F1 
and Cyclin A while increasing the level of the cell cycle inhibitor p16 (Galanti et al., 
2008). Furthermore, cannabinoids also showed to inhibit angiogenesis by decreasing 
VEGF levels (Blázquez et al., 2008). Additionally, cannabinoids have a role in the 
treatment of cancer as palliative interventions against nausea, vomiting, pain, anxiety, and 
sleep disturbances; and today’s scientific results suggest that cannabinoids could play an 
important role in palliative care of brain tumor patients (Likar and Nahler, 2017). 
 
5. Conclusions 
Cannabinoids are effective in reducing tumour growth in animal models of GBM. 
Besides, treatment efficacy was observed for different types of cannabinoids, alone or in 
combination, and different treatment durations. The results also showed the presence of 
publication bias, which, however, do not invalidate the efficacy of cannabinoids. These 
results in experimental GBM models are promising and highlights the importance of 
cannabinoid translational research which may lead to clinically relevant studies. 
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Table 1: Characteristics of the 22 included studies in this systematic review with meta-analysis. 
Study* Year Cells Intervention Outcome analysed Model used Dose (per day) 
Duration of 
the treatment 
López-Valero, et al A) 1) 2018 
Human GBM line (U87MG) 
Evaluation of the effect of cannabidiol (CBD) 
and tetrahydrocannabinol (THC) alone or in 
combination (CBD+THC), and in combination 
with temozolomide (TMZ) in apoptosis, 
migration, animal survival and tumour volume in 





CBD (15 mg/kg) 15 days 




(THC 6.5 mg/kg + 
CBD 24.5 mg/kg) 
14 days 




(THC 6.5 mg/kg + 
CBD 24.5 mg/kg) 
14 days 
López-Valero, et al B) 1) 2018 
Human GBM line (U87MG) 
 
Evaluation of the effect of CBD+THC (1:1) in 
combination of TMZ on tumour volume and 
animal survival in tumour xenogrfts 




THC (15 mg/kg) 15 days 




(THC 15 mg/kg + 








(THC 15 mg/kg + 
CBD 15 mg/kg), 
oral administration 
12 days 




(THC 45 mg/kg + 
CBD 45 mg/kg), 
oral administration 
12 days 




(THC 7.5 mg/kg + 
CBD 7.5 mg/kg) 
7 days 
Ossa, et al 1) 2013 
Human GBM line (U87MG) 
Evaluation of the effect of CBD, THC or 
CBD+THC (1:1), in solution or microparticles on 
apoptosis, migration, angiogenesis and on 
tumour volume of tumour xenografts 




THC (15 mg/kg) 22 days 
Ossa, et al 2) 2013 
Subcutaneous 
xenografts 
CBD (15 mg/kg) 22 days 




(THC 7.5 mg/kg + 
CBD 7.5 mg/kg) 
22 days 
Gurley, et al 1) 2012 
Human GBM line (U87MG) 
Evaluation of the effect of the cannabinoid KM-
233 on tumour volume of tumour xenografts 
(mice inoculated with U87MG cells) 







Gurley, et al 2) 2012 









Torres, et al 1) 2011 
Human GBM lines (U87MG 
and T98G) 
Evaluation of the effect of CBD, THC, alone or 
in combination with TMZ on 
viability/proliferation, apoptosis and tumour 
volume of tumour xenografts 




THC (15 mg/kg) 15 days 
Torres, et al 2) 2011 
Subcutaneous 
xenografts 
CBD (7.5 mg/kg) 15 days 
Torres, et al 3) 2011 
Subcutaneous 
xenografts 
THC (7.5 mg/kg) 15 days 




(THC 7.5 mg/kg + 
CBD 7.5 mg/kg) 
15 days 
Lorente, et al 1) 2011 
Human GBM lines (GOS3, 
U87MG, A172, SW1783, 
U118MG, U373MG, T98G and 
SW1088) 
Evaluation of the effect of THC on viability, 
apoptosis and tumour volume on tumour 
xenografts. Influence of expression levels of 






THC (15 mg/kg) 15 days 





THC (15 mg/kg) 15 days 
Massi, et al 2004 
Human GBM lines (U86MG 
and U373) 
Evaluation of the effect of CBD on proliferation, 
apoptosis and tumour volume on tumour 
xenografts 







Sánchez, et al  2001 
Human tumour cells prepared 
from a grade IV astrocytoma 
Evaluation of the effect of JWH-133 on tumour 
size of tumour xenografts 





(50 µg injected 
intratumourally/day) 
25 days 
Carracedo, et al  2006 
Human GBM line (U87MG) 
and mice embrionary fibroblasts 
(MEF) 
Evaluation of the effect of THC on viability, 
apoptosis and tumour volume on tumour 
xenografts 







THC (15 mg/kg) 14 days 
*The numbers in unpaired parenthesis indicate the division of each work in several studies. 
20 
 














for absence of 
bias  
(95% CI) 
Tumour volume  
(fold of increase) 
22 301 
-1.399 
(-1.900 to -0.898) 
<0.0001* 72 Random 
-1.606 
(-2.135 to -1.077) 



















Table 3: Subgroup analysis of the effects of cannabinoids on GBM growth. 
 




Number of studies 95% CI p-value I2 (%) 
Total 22 - - - 
WSDM observed - 
-1.399 
(-1.900 to -0.898) 
<0.0001* 72 
WSDM adjusted for 
absence of bias 
- 
-1.606 
(-2.135 to -1.077) 
- - 
Model used 
subcutaneous xenografts 20 
-1.512 
(-2.060 to -0.965) 
<0.0001* 74 
intracranial xenografts 2 
-0.738 





















(-2.039 to -0.564) 
0.001* 62 
Duration of the treatment (days) 
8 1 
-1.489 
















Table 4: Assessment of publication bias for the impact of cannabinoids administration 
on GBM growth. 
 
Outcome analysed 
Egger’s regression test 
95% CI t df p-value 
Tumour volume 
(fold of increase)  
-9.783 to -5.451 7.337 20 <0.00001* 






















Figure 1: Flow-diagram of database search, study selection and articles included in this 
systematic review with meta-analysis. 
 
 
*The work of López-Valero, et al 2018 B) was divided into 5 different studies. The work of Torres, et al 
2011 was divided into 4 different studies. The works of López-Valero, et al 2018 A) and Ossa, et al 2013 
were divided into 3 different studies. The works of Gurley, et al 2012 and Lorente, et al 2011 were divided 
into 2 different studies. (The division of each work in several studies is indicated by the numbers in unpaired 





Records identified through database 
searching 
(n=38) 
Additional records identified through 
other sources 
(n=2) 
Records after duplicates removed (n=40) 
Records screened (n=40) Records excluded (n=24) 
Full-text articles assessed for 
eligibility 
(n=16) 
Studies included in qualitative 
synthesis 
(n=9)  
Full-text articles excluded, with 
reasons (n=7): 
- inconsistency in presenting 
the results (tumour perimeter, 
weight, diameter) (n=3); 
- different study designs (n=3); 
- different summary statistics 
(median) (n=1). 


































































Heterogeneity: Tau2=0.993; Chi2=74.427; df=21; p-value<0.0001; I2=72% 
Test for overall effect: Z=-5.975; p-value<0.0001 
Study name Statistics for each study Std diff in means and 95% CI
Standard Std diff Lower Upper Relative 
error in means limit limit Z-Value p-Value weight
López-Valero, et al A) 1) 0,635 -1,815 -3,060 -0,570 -2,858 0,004 4,68
López-Valero, et al A) 2) 0,675 -1,945 -3,267 -0,623 -2,883 0,004 4,51
López-Valero, et al A) 3) 0,609 0,306 -0,887 1,500 0,503 0,615 4,79
López-Valero, et al B) 1) 0,657 -2,410 -3,698 -1,123 -3,669 0,000 4,58
López-Valero, et al B) 2) 0,577 -1,398 -2,529 -0,267 -2,423 0,015 4,92
López-Valero, et al B) 3) 0,547 -0,618 -1,691 0,454 -1,130 0,258 5,05
López-Valero, et al B) 4) 0,582 -1,218 -2,359 -0,077 -2,093 0,036 4,90
López-Valero, et al B) 5) 0,715 -1,489 -2,890 -0,088 -2,083 0,037 4,34
Ossa, et al 1) 0,573 -1,087 -2,210 0,035 -1,899 0,058 4,94
Ossa, et al 2) 0,589 -1,305 -2,459 -0,151 -2,217 0,027 4,87
Ossa, et al 3) 0,565 -0,969 -2,076 0,139 -1,715 0,086 4,98
Gurley, et al 4) 0,486 -0,008 -0,961 0,944 -0,017 0,986 5,31
Gurley, et al 5) 0,487 -0,197 -1,152 0,758 -0,404 0,686 5,31
Torres, et al 1) 0,721 -2,561 -3,974 -1,147 -3,551 0,000 4,32
Torres, et al 2) 0,564 -0,949 -2,054 0,156 -1,683 0,092 4,98
Torres, et al 3) 0,575 -1,127 -2,254 0,001 -1,958 0,050 4,93
Torres, et al 4) 0,947 -4,135 -5,991 -2,279 -4,367 0,000 3,46
Lorente, et al 1) 0,740 -1,720 -3,170 -0,269 -2,323 0,020 4,24
Lorente, et al 2) 0,637 0,345 -0,903 1,594 0,542 0,588 4,67
Massi, et al 0,538 -0,317 -1,371 0,737 -0,589 0,556 5,09
Sánchez, et al 1,473 -6,641 -9,528 -3,753 -4,507 0,000 2,06
Carracedo, et al 1,068 -5,336 -7,429 -3,244 -4,998 0,000 3,06
0,255 -1,399 -1,900 -0,898 -5,475 0,000
-10,00 -5,00 0,00 5,00 10,00
Favours cannabinoids Favours vehicle
Meta Analysis
Study name Statistics for each study Std diff in means and 95% CI
Standard Std diff Lower Upper Relative 
error in means limit limit Z-Value p-Value weight
López-Valero, et al A) 1) 0,635 -1,815 -3,060 -0,570 -2,858 0, 4 4,68
López-Valero, et al A) 2) 0,6 5 -1, 45 -3, 67 -0, 23 -2,883 0,004 4,51
López-Valero, et al A) 3) 0,609 0,306 -0,887 1, 00 0,5 3 0,615 4,79
López-Valero, et al B) 1) 0,657 -2,410 -3,6 8 -1,123 -3,669 0,000 4,58
López-Valero, et al B) 2) 0,577 -1,3 8 -2,529 -0,267 -2,423 0,015 4,92
López-Valero, et al B) 3) 0,547 -0,618 -1,691 0,4 4 -1,130 0,258 5,05
López-Valero, et al B) 4) 0,582 -1,218 -2,359 -0,077 -2,093 0,036 4,90
López-Valero, et al B) 5) 0,715 -1,489 -2,890 -0,088 -2,083 0,037 4,34
Ossa 1 0,573 -1, 7 -2,2 0 0,035 -1,899 0,058 4,94
Ossa 2 0,589 -1,305 -2,459 -0,151 -2,217 0,027 4,87
Ossa 3 0,565 -0,969 -2,076 0,139 -1,7 5 0, 86 4,98
Gurley, et al 4) 0,486 -0,008 -0,961 0,944 -0,017 0, 86 5,31
Gurley, et al 5) 0,487 -0,197 -1,152 0,758 -0,404 0,686 5, 1
Torres, et al 1) 0,721 -2,561 -3, 74 -1,147 -3,551 0, 0 4,32
Torres, t l 2) 0,564 -0,949 -2,054 0,156 -1,683 0,092 4,98
Torres, t l 3) 0,5 5 -1,127 -2,254 0,001 -1,958 0,050 4,93
Torres, et al 4) 0,947 -4, 35 -5,991 -2,2 9 -4,367 0,000 3,46
Lorente l 1) 0, 40 -1,720 -3,170 -0,269 -2,323 0, 20 4,24
Lo ente, et al 2) 0, 37 0, 45 -0,903 1,594 0,542 0,588 4, 7
Massi, et al 0, 38 -0,317 -1,371 0,737 -0,589 0,556 5,09
Sánchez, et al 1,473 -6,641 -9,528 -3,753 -4,507 0,000 2,06
Carracedo, et al 1,068 -5,336 -7,429 -3,244 -4,998 0,000 3,06
0,255 -1,399 -1,900 -0,898 -5,475 0,000
-10,00 -5,00 0,00 5,00 10,00





















Study name Statistics with study removed Std diff in means (95% CI) with study removed
Standard Lower Upper 
Point error limit limit Z-Value p-Value
López-Valero, et al A) 1) -1,384 0,266 -1,905 -0,863 -5,206 0,000
López-Valero, et al A) 2) -1,377 0,265 -1,896 -0,859 -5,206 0,000
López-Valero, et al A) 3) -1,479 0,258 -1,984 -0,974 -5,737 0,000
López-Valero, et al B) 1) -1,349 0,260 -1,859 -0,838 -5,179 0,000
López-Valero, et al B) 2) -1,408 0,269 -1,935 -0,881 -5,237 0,000
López-Valero, et al B) 3) -1,448 0,268 -1,974 -0,922 -5,398 0,000
López-Valero, et al B) 4) -1,417 0,269 -1,945 -0,890 -5,268 0,000
López-Valero, et al B) 5) -1,401 0,266 -1,923 -0,880 -5,265 0,000
Ossa, et al 1) -1,425 0,269 -1,952 -0,897 -5,289 0,000
Ossa, et al 2) -1,413 0,269 -1,939 -0,886 -5,255 0,000
Ossa, et al 3) -1,431 0,269 -1,959 -0,903 -5,312 0,000
Gurley, et al 4) -1,475 0,261 -1,987 -0,963 -5,647 0,000
Gurley, et al 5) -1,469 0,265 -1,987 -0,950 -5,551 0,000
Torres, et al 1) -1,344 0,259 -1,852 -0,836 -5,185 0,000
Torres, et al 2) -1,432 0,269 -1,960 -0,904 -5,316 0,000
Torres, et al 3) -1,422 0,269 -1,950 -0,895 -5,283 0,000
Torres, et al 4) -1,283 0,245 -1,764 -0,803 -5,236 0,000
Lorente, et al 1) -1,390 0,265 -1,909 -0,870 -5,244 0,000
Lorente, et al 2) -1,479 0,258 -1,984 -0,974 -5,739 0,000
Massi, et al -1,461 0,266 -1,982 -0,940 -5,498 0,000
Sánchez, et al -1,267 0,235 -1,728 -0,807 -5,392 0,000
Carracedo, et al -1,247 0,234 -1,705 -0,789 -5,338 0,000
-1,399 0,255 -1,900 -0,898 -5,475 0,000
-4,00 -2,00 0,00 2,00 4,00
Favours cannabinoids Favours vehicle
Meta Analysis
Study name Statistics with study removed Std diff in means (95% CI) with study removed
Standard Lower Upper 
Point error limit limit Z-Value p-Value
López-Valero, et al A) 1) -1,384 0,266 -1,905 -0,863 -5,206 , 0
López-Valero, et al A) 2) -1,377 0,265 -1,896 -0, 59 -5,206 , 0
López-Valero, et al A) 3) -1, 79 0,258 -1,984 -0,974 -5,737 , 0
López-Valero, et al B) 1) -1,349 0,260 -1,8 9 -0,838 -5,179 , 0
López-Valero, et al B) 2) -1,408 0,2 9 -1,9 5 -0, 81 -5,237 , 0
López-Valero, et al B) 3) -1,448 0,268 -1,974 -0, 22 -5,3 8 , 0
López-Valero, et al B) 4) -1,417 0,269 -1,945 -0, 90 -5,268 , 0
López-Valero, et al B) 5) -1,401 0,266 -1,923 -0,880 -5,265 , 0
Ossa 1 -1,425 0,269 -1,952 -0,897 -5,289 , 0
Ossa 2 -1,413 0,269 -1,939 -0,886 - ,255 , 0
Ossa, t l 3 -1, 31 0,269 -1,959 -0,903 -5,312 , 0
Gurley, et al 4) -1,475 0,261 -1,987 -0,963 -5,647 , 0
Gurley, et al 5) -1,469 0,265 -1,987 -0, 0 -5,551 , 0
Torres, et al 1) -1,344 0,2 9 -1,852 -0,8 6 -5,185 , 0
Torres, et al 2) -1,432 0,269 -1,960 -0,9 4 -5,316 , 0
Torres, et al 3) -1,422 0,269 -1,950 -0,895 -5,283 , 0
Torres, et al 4) -1,283 0,245 -1,764 -0,8 3 -5,236 , 0
Lorente, t l 1) -1,390 0,265 -1,909 -0,8 0 -5,244 , 0
Lorente, et al 2) -1, 9 0,258 -1,984 -0,974 -5,739 , 0
Massi, et al -1,461 0,266 -1,982 -0, 40 -5,498 , 0
Sánchez, et al -1,267 0,235 -1,728 -0,807 -5,392 0,000
Carracedo, et al -1,247 0,234 -1,705 -0,789 -5,338 0,000
-1,399 0,255 -1,900 -0,898 -5,475 0,000
-4,00 -2,00 0,00 2,00 4,00




Figure 4: Funnel plot of standard error by difference in means (publication bias tests) 
of the effects of cannabinoids on GBM growth. 
The blue circles indicate the observed studies and the red circles indicate the necessary imputed studies to 
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